Yan, Xiaocai
Managlia, Elizabeth
Carey, Galen
Barton, Norman
Tan, Xiao-Di
De Plaen, Isabelle G.
Article History
Received: 25 April 2023
Revised: 9 January 2024
Accepted: 12 January 2024
First Online: 28 February 2024
Competing interests
: I.G.D.P. received a grant from Shire Human Genetic Therapies, Inc., a member of the Takeda group of companies, for testing rhIGF-1/BP3 in experimental NEC. X.Y., E.M and X.D.T. have no competing interests to declare. G.C. and N.B. were full-time employees of Takeda and stockholders of Takeda Pharmaceutical Company Limited at the time of the study.